- Conditions
- Lung Cancer
- Interventions
- cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 93
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cancer
- Interventions
- CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin, CNTO888 + docetaxel
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Tacoma, Washington
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Drug
- Lead sponsor
- Laekna Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
- Conditions
- Gastric Cancer
- Interventions
- filgrastim, recombinant interferon alfa, docetaxel, doxorubicin hydrochloride, fluorouracil, hydroxyurea
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 24
- States / cities
- Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 18 more
- Conditions
- Lung Cancer
- Interventions
- Celecoxib, Docetaxel
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Head and Neck Cancer
- Interventions
- filgrastim, cisplatin, docetaxel, fluorouracil, paclitaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 96 more
- Conditions
- Prostate Cancer
- Interventions
- capivasertib, docetaxel, placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 37
- States / cities
- Yuma, Arizona • Beverly Hills, California • Cerritos, California + 31 more
- Conditions
- Advanced Cancer, Advanced Malignancies
- Interventions
- Cemiplimab, Hypofractionated radiotherapy, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed
- Drug · Radiation
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- docetaxel, lenalidomide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- alvocidib, docetaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 12
- States / cities
- Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more
- Conditions
- Hormone-refractory Prostate Cancer
- Interventions
- ILX651
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Lenexa, Kansas • Overland Park, Kansas + 8 more
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986360, Docetaxel, Nivolumab, Capecitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 8
- States / cities
- Los Angeles, California • New Orleans, Louisiana • Hackensack, New Jersey + 4 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
- Interventions
- FDG-PET, surgery, 5-FU, capecitabine, docetaxel, Irinotecan, 3D-CRT, IMRT
- Procedure · Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 71
- States / cities
- Los Angeles, California • St. Helena, California • Newark, Delaware + 47 more
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- ONC-392, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 33
- States / cities
- Springdale, Arkansas • Davis, California • Downey, California + 27 more
- Conditions
- Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
- Drug · Other · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 4 more
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Interventions
- FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 508
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
- Interventions
- I-131-1095, Enzalutamide
- Drug
- Lead sponsor
- Progenics Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 20
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 15 more
- Conditions
- Esophageal Cancer, Stomach Cancer
- Interventions
- Bevacizumab, Docetaxel, Cisplatin, Irinotecan
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- MDV3100
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 3
- States / cities
- New York, New York • Norfolk, Virginia
- Conditions
- Head and Neck Cancer
- Interventions
- ASP-1929 Photoimmunotherapy, Physician's Choice SOC
- Combination Product · Drug
- Lead sponsor
- Rakuten Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more
- Conditions
- Breast Cancer, Breast Cancer Female
- Interventions
- Standard of Care: Docetaxel, Standard of Care: Cyclophosphamide, Function Assessment of Cancer Therapy (FACT) Surveys
- Drug · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida